A complete and durable response to denileukin diftitox in a patient with mycosis fungoides.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 12582402.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
We describe a patient with stage IA mycosis fungoides treated with denileukin diftitox as part of a randomized phase III trial. The patient had a rapid and complete response and has remained in remission for more than 5 years without maintenance therapy. Although denileukin diftitox is not usually considered for patients with early-stage mycosis fungoides, our experience provides anecdotal evidence that fusion toxin therapy may be worth considering as a treatment for patients with stage I disease.
Medical subject headings
- Antineoplastic Agents
- Diphtheria Toxin
- Interleukin-2
- Mycosis Fungoides
- Recombinant Fusion Proteins